TRACON PHARMACEUTICALS INC's ticker is TCON and the CUSIP is 89237H209. A total of 27 filers reported holding TRACON PHARMACEUTICALS INC in Q3 2020. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $848,082 | -38.8% | 4,764,508 | 0.0% | 0.28% | -16.9% |
| Q2 2023 | $1,386,472 | -84.6% | 4,764,508 | 0.0% | 0.33% | -87.7% |
| Q1 2023 | $9,004,920 | +31.7% | 4,764,508 | +3.8% | 2.70% | +13.4% |
| Q4 2022 | $6,839,100 | -2.3% | 4,590,000 | +9.5% | 2.38% | -17.7% |
| Q3 2022 | $6,997,000 | -15.2% | 4,190,000 | +1.6% | 2.89% | -22.3% |
| Q2 2022 | $8,251,000 | -0.6% | 4,125,322 | +30.8% | 3.72% | +44.3% |
| Q1 2022 | $8,298,000 | -1.9% | 3,155,098 | +3.3% | 2.58% | +43.6% |
| Q4 2021 | $8,462,000 | -13.2% | 3,055,000 | +21.3% | 1.80% | -1.4% |
| Q3 2021 | $9,746,000 | -40.4% | 2,518,371 | 0.0% | 1.82% | -33.0% |
| Q2 2021 | $16,344,000 | -21.1% | 2,518,371 | 0.0% | 2.72% | -10.8% |
| Q1 2021 | $20,726,000 | -29.7% | 2,518,371 | 0.0% | 3.04% | -20.9% |
| Q4 2020 | $29,465,000 | +183.1% | 2,518,371 | +25.1% | 3.85% | +89.0% |
| Q3 2020 | $10,409,000 | – | 2,013,438 | – | 2.04% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Opaleye Management Inc. | 4,125,322 | $8,251,000 | 3.72% |
| Ikarian Capital, LLC | 2,788,853 | $5,577,000 | 1.02% |
| Telemetry Investments, L.L.C. | 100,000 | $200,000 | 0.24% |
| ACT CAPITAL MANAGEMENT, LLC | 28,500 | $57,000 | 0.08% |
| JOHNSON & JOHNSON | 84,003 | $168,000 | 0.04% |
| NEA Management Company, LLC | 346,719 | $693,000 | 0.04% |
| X-Square Capital, LLC | 17,973 | $36,000 | 0.02% |
| BOOTHBAY FUND MANAGEMENT, LLC | 268,301 | $537,000 | 0.01% |
| LINDEN ADVISORS LP | 454,916 | $910,000 | 0.01% |
| DOWLING & YAHNKE LLC | 47,455 | $95,000 | 0.00% |